Century Therapeutics, Inc. Interest Receivable
Century Therapeutics, Inc. (IPSC) had Interest Receivable of $393.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2026-03-12
- 2025-12-31: Interest Receivable $393.00K.
- 2024-12-31: Interest Receivable $1.25M.
- 2023-12-31: Interest Receivable $1.57M.
- 2023-09-30: Interest Receivable $1.54M.
| Period end | Interest Receivable |
|---|---|
| 2025-12-31 | $393.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $1.25M 10-K · filed 2026-03-12 |
| 2023-12-31 | $1.57M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.54M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.13M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $855.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |